Glaxo Wins Battle Over Asthma Drug

GlaxoSmithKline scored a minor victory in the battle to keep sales of its $9 billion-a-year asthma treatment Advair from being lost to generic competitors.

Leave a Reply

Your email address will not be published. Required fields are marked *